APO Research
Talk to an analyst

APO RESEARCH · REPORT

Lung Cancer Diagnostic And Screening

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Lung Cancer Diagnostic And Screening Market Analysis and Forecast 2026-2032

5 March 2026206 pages

Choose your research edition.

Industry ResearchLung Cancer Diagnostic And Screening Industry Research Report 2026132 pages · $2,950 USDIndustry Growth & TrendsGlobal Lung Cancer Diagnostic And Screening Industry Growth and Trends Forecast to 2032114 pages · $3,450 USDMarket StructureGlobal Lung Cancer Diagnostic And Screening Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032198 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Lung Cancer Diagnostic And Screening Market Outlook and Growth Opportunities 2026204 pages · $4,250 USDMarket Analysis & ForecastGlobal Lung Cancer Diagnostic And Screening Market Analysis and Forecast 2026-2032206 pages · $4,950 USD

Market perspective

The global Lung Cancer Diagnostic And Screening market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Lung Cancer Diagnostic And Screening is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Lung Cancer Diagnostic And Screening is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Lung Cancer Diagnostic And Screening is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Lung Cancer Diagnostic And Screening is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Lung Cancer Diagnostic And Screening include Pfizer, F.Hoffmann-La Roche AG, Bristol-Myers Squibb Company, Thermo Fisher Scientific, AstraZeneca Plc, Abbott Laboratories, Medtronic Plc, Danaher Corporation and Siemens Healthcare GmbH, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Lung Cancer Diagnostic And Screening, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Lung Cancer Diagnostic And Screening, also provides the revenue of main regions and countries. Of the upcoming market potential for Lung Cancer Diagnostic And Screening, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Lung Cancer Diagnostic And Screening revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Lung Cancer Diagnostic And Screening market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Lung Cancer Diagnostic And Screening revenue, projected growth trends, production technology, application and end-user industry.

Lung Cancer Diagnostic And Screening Segment by Company

Pfizer

F.Hoffmann-La Roche AG

Bristol-Myers Squibb Company

Thermo Fisher Scientific

AstraZeneca Plc

Abbott Laboratories

Medtronic Plc

Danaher Corporation

Siemens Healthcare GmbH

FUJIFILM Corporation

KoninklijikePhilips N.V.

GE Healthcare Bio Sciences AB

Quest Diagnostics lIncorporated

Agilent Technologies lnc

Qiagen Inc.

Myriad Genetic Laboratories Inc.

NeoGenomics Laboratories Inc

Canon MedicalSystems Corporation

Eon Health Inc

Lung Cancer Diagnostic And Screening Segment by Type

Instrument

Consumables and Accessories

Lung Cancer Diagnostic And Screening Segment by Application

Hospital

Independent Diagnostic Laboratory

Lung Cancer Diagnostic And Screening Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Lung Cancer Diagnostic And Screening market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Lung Cancer Diagnostic And Screening and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Lung Cancer Diagnostic And Screening.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Lung Cancer Diagnostic And Screening in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Lung Cancer Diagnostic And Screening company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Lung Cancer Diagnostic And Screening revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Lung Cancer Diagnostic And Screening Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Instrument Major Player Table 3. Consumables and Accessories Major Player Table 4. Global Lung Cancer Diagnostic And Screening Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 5. Hospital Major Player Table 6. Independent Diagnostic Laboratory Major Player Table 7. Lung Cancer Diagnostic And Screening Industry Trends Table 8. Lung Cancer Diagnostic And Screening Industry Drivers Table 9. Lung Cancer Diagnostic And Screening Industry Opportunities and Challenges Table 10. Lung Cancer Diagnostic And Screening Industry Restraints Table 11. Global Lung Cancer Diagnostic And Screening Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 12. Global Lung Cancer Diagnostic And Screening Market Size by Region (2021-2026) & (US$ Million) Table 13. Global Lung Cancer Diagnostic And Screening Market Share by Region (2021-2026) Table 14. Global Lung Cancer Diagnostic And Screening Market Size by Region (2027-2032) & (US$ Million) Table 15. Global Lung Cancer Diagnostic And Screening Market Share by Region (2027-2032) Table 16. Global Lung Cancer Diagnostic And Screening Revenue by Players (US$ Million) & (2021-2026) Table 17. Global Lung Cancer Diagnostic And Screening Revenue Market Share by Players (2021-2026) Table 18. Global Lung Cancer Diagnostic And Screening Key Players Ranking, 2024 VS 2025 VS 2026 Table 19. Global Lung Cancer Diagnostic And Screening Key Players Headquarters & Area Served Table 20. Global Lung Cancer Diagnostic And Screening Players, Product Type & Application Table 21. Global Lung Cancer Diagnostic And Screening Players Establishment Date Table 22. Global Players Market Concentration Ratio (CR5 and HHI) Table 23. Global Lung Cancer Diagnostic And Screening by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 24. Global Lung Cancer Diagnostic And Screening Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Lung Cancer Diagnostic And Screening Revenue by Type (2021-2026) & (US$ Million) Table 26. Global Lung Cancer Diagnostic And Screening Revenue by Type (2027-2032) & (US$ Million) Table 27. Global Lung Cancer Diagnostic And Screening Revenue Market Share by Type (2021-2026) Table 28. Global Lung Cancer Diagnostic And Screening Revenue Market Share by Type (2027-2032) Table 29. Global Lung Cancer Diagnostic And Screening Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 30. Global Lung Cancer Diagnostic And Screening Revenue by Application (2021-2026) & (US$ Million) Table 31. Global Lung Cancer Diagnostic And Screening Revenue by Application (2027-2032) & (US$ Million) Table 32. Global Lung Cancer Diagnostic And Screening Revenue Market Share by Application (2021-2026) Table 33. Global Lung Cancer Diagnostic And Screening Revenue Market Share by Application (2027-2032) Table 34. Pfizer Company Information Table 35. Pfizer Business Overview Table 36. Pfizer Lung Cancer Diagnostic And Screening Revenue and Gross Margin (US$ Million) & (2021-2026) Table 37. Pfizer Lung Cancer Diagnostic And Screening Product Portfolio Table 38. Pfizer Recent Development Table 39. F.Hoffmann-La Roche AG Company Information Table 40. F.Hoffmann-La Roche AG Business Overview Table 41. F.Hoffmann-La Roche AG Lung Cancer Diagnostic And Screening Revenue and Gross Margin (US$ Million) & (2021-2026) Table 42. F.Hoffmann-La Roche AG Lung Cancer Diagnostic And Screening Product Portfolio Table 43. F.Hoffmann-La Roche AG Recent Development Table 44. Bristol-Myers Squibb Company Company Information Table 45. Bristol-Myers Squibb Company Business Overview Table 46. Bristol-Myers Squibb Company Lung Cancer Diagnostic And Screening Revenue and Gross Margin (US$ Million) & (2021-2026) Table 47. Bristol-Myers Squibb Company Lung Cancer Diagnostic And Screening Product Portfolio Table 48. Bristol-Myers Squibb Company Recent Development Table 49. Thermo Fisher Scientific Company Information Table 50. Thermo Fisher Scientific Business Overview Table 51. Thermo Fisher Scientific Lung Cancer Diagnostic And Screening Revenue and Gross Margin (US$ Million) & (2021-2026) Table 52. Thermo Fisher Scientific Lung Cancer Diagnostic And Screening Product Portfolio Table 53. Thermo Fisher Scientific Recent Development Table 54. AstraZeneca Plc Company Information Table 55. AstraZeneca Plc Business Overview Table 56. AstraZeneca Plc Lung Cancer Diagnostic And Screening Revenue and Gross Margin (US$ Million) & (2021-2026) Table 57. AstraZeneca Plc Lung Cancer Diagnostic And Screening Product Portfolio Table 58. AstraZeneca Plc Recent Development Table 59. Abbott Laboratories Company Information Table 60. Abbott Laboratories Business Overview Table 61. Abbott Laboratories Lung Cancer Diagnostic And Screening Revenue and Gross Margin (US$ Million) & (2021-2026) Table 62. Abbott Laboratories Lung Cancer Diagnostic And Screening Product Portfolio Table 63. Abbott Laboratories Recent Development Table 64. Medtronic Plc Company Information Table 65. Medtronic Plc Business Overview Table 66. Medtronic Plc Lung Cancer Diagnostic And Screening Revenue and Gross Margin (US$ Million) & (2021-2026) Table 67. Medtronic Plc Lung Cancer Diagnostic And Screening Product Portfolio Table 68. Medtronic Plc Recent Development Table 69. Danaher Corporation Company Information Table 70. Danaher Corporation Business Overview Table 71. Danaher Corporation Lung Cancer Diagnostic And Screening Revenue and Gross Margin (US$ Million) & (2021-2026) Table 72. Danaher Corporation Lung Cancer Diagnostic And Screening Product Portfolio Table 73. Danaher Corporation Recent Development Table 74. Siemens Healthcare GmbH Company Information Table 75. Siemens Healthcare GmbH Business Overview Table 76. Siemens Healthcare GmbH Lung Cancer Diagnostic And Screening Revenue and Gross Margin (US$ Million) & (2021-2026) Table 77. Siemens Healthcare GmbH Lung Cancer Diagnostic And Screening Product Portfolio Table 78. Siemens Healthcare GmbH Recent Development Table 79. FUJIFILM Corporation Company Information Table 80. FUJIFILM Corporation Business Overview Table 81. FUJIFILM Corporation Lung Cancer Diagnostic And Screening Revenue and Gross Margin (US$ Million) & (2021-2026) Table 82. FUJIFILM Corporation Lung Cancer Diagnostic And Screening Product Portfolio Table 83. FUJIFILM Corporation Recent Development Table 84. KoninklijikePhilips N.V. Company Information Table 85. KoninklijikePhilips N.V. Business Overview Table 86. KoninklijikePhilips N.V. Lung Cancer Diagnostic And Screening Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 87. KoninklijikePhilips N.V. Lung Cancer Diagnostic And Screening Product Portfolio Table 88. KoninklijikePhilips N.V. Recent Development Table 89. GE Healthcare Bio Sciences AB Company Information Table 90. GE Healthcare Bio Sciences AB Business Overview Table 91. GE Healthcare Bio Sciences AB Lung Cancer Diagnostic And Screening Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 92. GE Healthcare Bio Sciences AB Lung Cancer Diagnostic And Screening Product Portfolio Table 93. GE Healthcare Bio Sciences AB Recent Development Table 94. Quest Diagnostics lIncorporated Company Information Table 95. Quest Diagnostics lIncorporated Business Overview Table 96. Quest Diagnostics lIncorporated Lung Cancer Diagnostic And Screening Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 97. Quest Diagnostics lIncorporated Lung Cancer Diagnostic And Screening Product Portfolio Table 98. Quest Diagnostics lIncorporated Recent Development Table 99. Agilent Technologies lnc Company Information Table 100. Agilent Technologies lnc Business Overview Table 101. Agilent Technologies lnc Lung Cancer Diagnostic And Screening Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 102. Agilent Technologies lnc Lung Cancer Diagnostic And Screening Product Portfolio Table 103. Agilent Technologies lnc Recent Development Table 104. Qiagen Inc. Company Information Table 105. Qiagen Inc. Business Overview Table 106. Qiagen Inc. Lung Cancer Diagnostic And Screening Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 107. Qiagen Inc. Lung Cancer Diagnostic And Screening Product Portfolio Table 108. Qiagen Inc. Recent Development Table 109. Myriad Genetic Laboratories Inc. Company Information Table 110. Myriad Genetic Laboratories Inc. Business Overview Table 111. Myriad Genetic Laboratories Inc. Lung Cancer Diagnostic And Screening Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 112. Myriad Genetic Laboratories Inc. Lung Cancer Diagnostic And Screening Product Portfolio Table 113. Myriad Genetic Laboratories Inc. Recent Development Table 114. NeoGenomics Laboratories Inc Company Information Table 115. NeoGenomics Laboratories Inc Business Overview Table 116. NeoGenomics Laboratories Inc Lung Cancer Diagnostic And Screening Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 117. NeoGenomics Laboratories Inc Lung Cancer Diagnostic And Screening Product Portfolio Table 118. NeoGenomics Laboratories Inc Recent Development Table 119. Canon MedicalSystems Corporation Company Information Table 120. Canon MedicalSystems Corporation Business Overview Table 121. Canon MedicalSystems Corporation Lung Cancer Diagnostic And Screening Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 122. Canon MedicalSystems Corporation Lung Cancer Diagnostic And Screening Product Portfolio Table 123. Canon MedicalSystems Corporation Recent Development Table 124. Eon Health Inc Company Information Table 125. Eon Health Inc Business Overview Table 126. Eon Health Inc Lung Cancer Diagnostic And Screening Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 127. Eon Health Inc Lung Cancer Diagnostic And Screening Product Portfolio Table 128. Eon Health Inc Recent Development Table 129. North America Lung Cancer Diagnostic And Screening Revenue by Type (2021-2026) & (US$ Million) Table 130. North America Lung Cancer Diagnostic And Screening Revenue by Type (2027-2032) & (US$ Million) Table 131. North America Lung Cancer Diagnostic And Screening Revenue by Application (2021-2026) & (US$ Million) Table 132. North America Lung Cancer Diagnostic And Screening Revenue by Application (2027-2032) & (US$ Million) Table 133. North America Lung Cancer Diagnostic And Screening Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 134. North America Lung Cancer Diagnostic And Screening Revenue by Country (2021-2026) & (US$ Million) Table 135. North America Lung Cancer Diagnostic And Screening Revenue by Country (US$ Million) & (2027-2032) Table 136. Europe Lung Cancer Diagnostic And Screening Revenue by Type (2021-2026) & (US$ Million) Table 137. Europe Lung Cancer Diagnostic And Screening Revenue by Type (2027-2032) & (US$ Million) Table 138. Europe Lung Cancer Diagnostic And Screening Revenue by Application (2021-2026) & (US$ Million) Table 139. Europe Lung Cancer Diagnostic And Screening Revenue by Application (2027-2032) & (US$ Million) Table 140. Europe Lung Cancer Diagnostic And Screening Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 141. Europe Lung Cancer Diagnostic And Screening Revenue by Country (2021-2026) & (US$ Million) Table 142. Europe Lung Cancer Diagnostic And Screening Revenue by Country (US$ Million) & (2027-2032) Table 143. China Lung Cancer Diagnostic And Screening Revenue by Type (2021-2026) & (US$ Million) Table 144. China Lung Cancer Diagnostic And Screening Revenue by Type (2027-2032) & (US$ Million) Table 145. China Lung Cancer Diagnostic And Screening Revenue by Application (2021-2026) & (US$ Million) Table 146. China Lung Cancer Diagnostic And Screening Revenue by Application (2027-2032) & (US$ Million) Table 147. Asia Lung Cancer Diagnostic And Screening Revenue by Type (2021-2026) & (US$ Million) Table 148. Asia Lung Cancer Diagnostic And Screening Revenue by Type (2027-2032) & (US$ Million) Table 149. Asia Lung Cancer Diagnostic And Screening Revenue by Application (2021-2026) & (US$ Million) Table 150. Asia Lung Cancer Diagnostic And Screening Revenue by Application (2027-2032) & (US$ Million) Table 151. Asia Lung Cancer Diagnostic And Screening Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 152. Asia Lung Cancer Diagnostic And Screening Revenue by Region (US$ Million) & (2021-2026) Table 153. Asia Lung Cancer Diagnostic And Screening Revenue by Region (US$ Million) & (2027-2032) Table 154. SAMEA Lung Cancer Diagnostic And Screening Revenue by Type (2021-2026) & (US$ Million) Table 155. SAMEA Lung Cancer Diagnostic And Screening Revenue by Type (2027-2032) & (US$ Million) Table 156. SAMEA Lung Cancer Diagnostic And Screening Revenue by Application (2021-2026) & (US$ Million) Table 157. SAMEA Lung Cancer Diagnostic And Screening Revenue by Application (2027-2032) & (US$ Million) Table 158. SAMEA Lung Cancer Diagnostic And Screening Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 159. SAMEA Lung Cancer Diagnostic And Screening Revenue by Country (2021-2026) & (US$ Million) Table 160. SAMEA Lung Cancer Diagnostic And Screening Revenue by Country (US$ Million) & (2027-2032) Table 161. Research Programs/Design for This Report Table 162. Authors List of This Report Table 163. Secondary Sources Table 164. Primary Sources List of Figures Figure 1. Lung Cancer Diagnostic And Screening Image Figure 2. Global Lung Cancer Diagnostic And Screening Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Lung Cancer Diagnostic And Screening Market Size Share 2021 VS 2025 VS 2032 Figure 4. Instrument Image Figure 5. Consumables and Accessories Image Figure 6. Global Lung Cancer Diagnostic And Screening Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 7. Global Lung Cancer Diagnostic And Screening Market Size Share 2021 VS 2025 VS 2032 Figure 8. Hospital Image Figure 9. Independent Diagnostic Laboratory Image Figure 10. Global Lung Cancer Diagnostic And Screening Market Size (US$ Million) & (2021-2032) Figure 11. Global Lung Cancer Diagnostic And Screening Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 12. Global Lung Cancer Diagnostic And Screening Market Share by Region: 2021 VS 2025 VS 2032 Figure 13. Global Lung Cancer Diagnostic And Screening Players Revenue Share Top 10 and Top 5 in 2025 Figure 14. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 15. Global Lung Cancer Diagnostic And Screening Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global Lung Cancer Diagnostic And Screening Revenue Market Share 2021 VS 2025 VS 2032 Figure 17. Global Lung Cancer Diagnostic And Screening Revenue Market Share by Type (2021-2032) Figure 18. Global Lung Cancer Diagnostic And Screening Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 19. Global Lung Cancer Diagnostic And Screening Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 20. Global Lung Cancer Diagnostic And Screening Revenue Market Share by Application (2021-2032) Figure 21. North America Lung Cancer Diagnostic And Screening Revenue YoY Growth (2021-2032) & (US$ Million) Figure 22. North America Lung Cancer Diagnostic And Screening Revenue Share by Type (2021-2032) Figure 23. North America Lung Cancer Diagnostic And Screening Revenue Share by Application (2021-2032) Figure 24. North America Lung Cancer Diagnostic And Screening Revenue Share by Country (2021-2032) Figure 25. United States Lung Cancer Diagnostic And Screening Revenue YoY Growth (US$ Million) & (2021-2032) Figure 26. Canada Lung Cancer Diagnostic And Screening Revenue YoY Growth (US$ Million) & (2021-2032) Figure 27. Mexico Lung Cancer Diagnostic And Screening Revenue YoY Growth (US$ Million) & (2021-2032) Figure 28. Europe Lung Cancer Diagnostic And Screening Revenue YoY Growth (2021-2032) & (US$ Million) Figure 29. Europe Lung Cancer Diagnostic And Screening Revenue Share by Type (2021-2032) Figure 30. Europe Lung Cancer Diagnostic And Screening Revenue Share by Application (2021-2032) Figure 31. Europe Lung Cancer Diagnostic And Screening Revenue Share by Country (2021-2032) Figure 32. Germany Lung Cancer Diagnostic And Screening Revenue YoY Growth (US$ Million) & (2021-2032) Figure 33. France Lung Cancer Diagnostic And Screening Revenue YoY Growth (US$ Million) & (2021-2032) Figure 34. U.K. Lung Cancer Diagnostic And Screening Revenue YoY Growth (US$ Million) & (2021-2032) Figure 35. Italy Lung Cancer Diagnostic And Screening Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. Spain Lung Cancer Diagnostic And Screening Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. Russia Lung Cancer Diagnostic And Screening Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Netherlands Lung Cancer Diagnostic And Screening Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Nordic Countries Lung Cancer Diagnostic And Screening Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. China Lung Cancer Diagnostic And Screening Revenue YoY Growth (2021-2032) & (US$ Million) Figure 41. China Lung Cancer Diagnostic And Screening Revenue Share by Type (2021-2032) Figure 42. China Lung Cancer Diagnostic And Screening Revenue Share by Application (2021-2032) Figure 43. Asia Lung Cancer Diagnostic And Screening Revenue YoY Growth (2021-2032) & (US$ Million) Figure 44. Asia Lung Cancer Diagnostic And Screening Revenue Share by Type (2021-2032) Figure 45. Asia Lung Cancer Diagnostic And Screening Revenue Share by Application (2021-2032) Figure 46. Asia Lung Cancer Diagnostic And Screening Revenue Share by Region (2021-2032) Figure 47. Japan Lung Cancer Diagnostic And Screening Revenue YoY Growth (US$ Million) & (2021-2032) Figure 48. South Korea Lung Cancer Diagnostic And Screening Revenue YoY Growth (US$ Million) & (2021-2032) Figure 49. India Lung Cancer Diagnostic And Screening Revenue YoY Growth (US$ Million) & (2021-2032) Figure 50. Australia Lung Cancer Diagnostic And Screening Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. Taiwan Lung Cancer Diagnostic And Screening Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. Southeast Asia Lung Cancer Diagnostic And Screening Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. SAMEA Lung Cancer Diagnostic And Screening Revenue YoY Growth (2021-2032) & (US$ Million) Figure 54. SAMEA Lung Cancer Diagnostic And Screening Revenue Share by Type (2021-2032) Figure 55. SAMEA Lung Cancer Diagnostic And Screening Revenue Share by Application (2021-2032) Figure 56. SAMEA Lung Cancer Diagnostic And Screening Revenue Share by Country (2021-2032) Figure 57. Brazil Lung Cancer Diagnostic And Screening Revenue YoY Growth (US$ Million) & (2021-2032) Figure 58. Argentina Lung Cancer Diagnostic And Screening Revenue YoY Growth (US$ Million) & (2021-2032) Figure 59. Chile Lung Cancer Diagnostic And Screening Revenue YoY Growth (US$ Million) & (2021-2032) Figure 60. Colombia Lung Cancer Diagnostic And Screening Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Peru Lung Cancer Diagnostic And Screening Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Saudi Arabia Lung Cancer Diagnostic And Screening Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Israel Lung Cancer Diagnostic And Screening Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. UAE Lung Cancer Diagnostic And Screening Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Turkey Lung Cancer Diagnostic And Screening Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Iran Lung Cancer Diagnostic And Screening Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Egypt Lung Cancer Diagnostic And Screening Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Years Considered Figure 69. Research Process Figure 70. Key Executives Interviewed

Scope & coverage.

Types
  • Instrument
  • Consumables and Accessories
Applications
  • Hospital
  • Independent Diagnostic Laboratory
Companies covered
  • Pfizer
  • F.Hoffmann-La Roche AG
  • Bristol-Myers Squibb Company
  • Thermo Fisher Scientific
  • AstraZeneca Plc
  • Abbott Laboratories
  • Medtronic Plc
  • Danaher Corporation
  • Siemens Healthcare GmbH
  • FUJIFILM Corporation
  • KoninklijikePhilips N.V.
  • GE Healthcare Bio Sciences AB
  • Quest Diagnostics lIncorporated
  • Agilent Technologies lnc
  • Qiagen Inc.
  • Myriad Genetic Laboratories Inc.
  • NeoGenomics Laboratories Inc
  • Canon MedicalSystems Corporation
  • Eon Health Inc

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Lung Cancer Diagnostic And Screening Market by Type
  3. 1.2.1 Global Lung Cancer Diagnostic And Screening Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Instrument
  5. 1.2.3 Consumables and Accessories
  6. 1.3 Lung Cancer Diagnostic And Screening Market by Application
  7. 1.3.1 Global Lung Cancer Diagnostic And Screening Market Size by Application, 2021 VS 2025 VS 2032
  8. 1.3.2 Hospital
  9. 1.3.3 Independent Diagnostic Laboratory
  10. 1.4 Assumptions and Limitations
  11. 1.5 Study Goals and Objectives
2 Lung Cancer Diagnostic And Screening Market Dynamics
  1. 2.1 Lung Cancer Diagnostic And Screening Industry Trends
  2. 2.2 Lung Cancer Diagnostic And Screening Industry Drivers
  3. 2.3 Lung Cancer Diagnostic And Screening Industry Opportunities and Challenges
  4. 2.4 Lung Cancer Diagnostic And Screening Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Lung Cancer Diagnostic And Screening Market Perspective (2021-2032)
  2. 3.2 Global Lung Cancer Diagnostic And Screening Growth Trends by Region
  3. 3.2.1 Global Lung Cancer Diagnostic And Screening Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Lung Cancer Diagnostic And Screening Market Size by Region (2021-2026)
  5. 3.2.3 Global Lung Cancer Diagnostic And Screening Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Lung Cancer Diagnostic And Screening Revenue by Players
  2. 4.1.1 Global Lung Cancer Diagnostic And Screening Revenue by Players (2021-2026)
  3. 4.1.2 Global Lung Cancer Diagnostic And Screening Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Lung Cancer Diagnostic And Screening Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Lung Cancer Diagnostic And Screening Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Lung Cancer Diagnostic And Screening Key Players Headquarters & Area Served
  7. 4.4 Global Lung Cancer Diagnostic And Screening Players, Product Type & Application
  8. 4.5 Global Lung Cancer Diagnostic And Screening Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Lung Cancer Diagnostic And Screening Market CR5 and HHI
  11. 4.6.3 2025 Lung Cancer Diagnostic And Screening Tier 1, Tier 2, and Tier 3
5 Lung Cancer Diagnostic And Screening Market Size by Type
  1. 5.1 Global Lung Cancer Diagnostic And Screening Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Lung Cancer Diagnostic And Screening Revenue by Type (2021-2032)
  3. 5.3 Global Lung Cancer Diagnostic And Screening Revenue Market Share by Type (2021-2032)
6 Lung Cancer Diagnostic And Screening Market Size by Application
  1. 6.1 Global Lung Cancer Diagnostic And Screening Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Lung Cancer Diagnostic And Screening Revenue by Application (2021-2032)
  3. 6.3 Global Lung Cancer Diagnostic And Screening Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Pfizer
  2. 7.1.1 Pfizer Company Information
  3. 7.1.2 Pfizer Business Overview
  4. 7.1.3 Pfizer Lung Cancer Diagnostic And Screening Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Pfizer Lung Cancer Diagnostic And Screening Product Portfolio
  6. 7.1.5 Pfizer Recent Developments
  7. 7.2 F.Hoffmann-La Roche AG
  8. 7.2.1 F.Hoffmann-La Roche AG Company Information
  9. 7.2.2 F.Hoffmann-La Roche AG Business Overview
  10. 7.2.3 F.Hoffmann-La Roche AG Lung Cancer Diagnostic And Screening Revenue and Gross Margin (2021-2026)
  11. 7.2.4 F.Hoffmann-La Roche AG Lung Cancer Diagnostic And Screening Product Portfolio
  12. 7.2.5 F.Hoffmann-La Roche AG Recent Developments
  13. 7.3 Bristol-Myers Squibb Company
  14. 7.3.1 Bristol-Myers Squibb Company Company Information
  15. 7.3.2 Bristol-Myers Squibb Company Business Overview
  16. 7.3.3 Bristol-Myers Squibb Company Lung Cancer Diagnostic And Screening Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Bristol-Myers Squibb Company Lung Cancer Diagnostic And Screening Product Portfolio
  18. 7.3.5 Bristol-Myers Squibb Company Recent Developments
  19. 7.4 Thermo Fisher Scientific
  20. 7.4.1 Thermo Fisher Scientific Company Information
  21. 7.4.2 Thermo Fisher Scientific Business Overview
  22. 7.4.3 Thermo Fisher Scientific Lung Cancer Diagnostic And Screening Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Thermo Fisher Scientific Lung Cancer Diagnostic And Screening Product Portfolio
  24. 7.4.5 Thermo Fisher Scientific Recent Developments
  25. 7.5 AstraZeneca Plc
  26. 7.5.1 AstraZeneca Plc Company Information
  27. 7.5.2 AstraZeneca Plc Business Overview
  28. 7.5.3 AstraZeneca Plc Lung Cancer Diagnostic And Screening Revenue and Gross Margin (2021-2026)
  29. 7.5.4 AstraZeneca Plc Lung Cancer Diagnostic And Screening Product Portfolio
  30. 7.5.5 AstraZeneca Plc Recent Developments
  31. 7.6 Abbott Laboratories
  32. 7.6.1 Abbott Laboratories Company Information
  33. 7.6.2 Abbott Laboratories Business Overview
  34. 7.6.3 Abbott Laboratories Lung Cancer Diagnostic And Screening Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Abbott Laboratories Lung Cancer Diagnostic And Screening Product Portfolio
  36. 7.6.5 Abbott Laboratories Recent Developments
  37. 7.7 Medtronic Plc
  38. 7.7.1 Medtronic Plc Company Information
  39. 7.7.2 Medtronic Plc Business Overview
  40. 7.7.3 Medtronic Plc Lung Cancer Diagnostic And Screening Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Medtronic Plc Lung Cancer Diagnostic And Screening Product Portfolio
  42. 7.7.5 Medtronic Plc Recent Developments
  43. 7.8 Danaher Corporation
  44. 7.8.1 Danaher Corporation Company Information
  45. 7.8.2 Danaher Corporation Business Overview
  46. 7.8.3 Danaher Corporation Lung Cancer Diagnostic And Screening Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Danaher Corporation Lung Cancer Diagnostic And Screening Product Portfolio
  48. 7.8.5 Danaher Corporation Recent Developments
  49. 7.9 Siemens Healthcare GmbH
  50. 7.9.1 Siemens Healthcare GmbH Company Information
  51. 7.9.2 Siemens Healthcare GmbH Business Overview
  52. 7.9.3 Siemens Healthcare GmbH Lung Cancer Diagnostic And Screening Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Siemens Healthcare GmbH Lung Cancer Diagnostic And Screening Product Portfolio
  54. 7.9.5 Siemens Healthcare GmbH Recent Developments
  55. 7.10 FUJIFILM Corporation
  56. 7.10.1 FUJIFILM Corporation Company Information
  57. 7.10.2 FUJIFILM Corporation Business Overview
  58. 7.10.3 FUJIFILM Corporation Lung Cancer Diagnostic And Screening Revenue and Gross Margin (2021-2026)
  59. 7.10.4 FUJIFILM Corporation Lung Cancer Diagnostic And Screening Product Portfolio
  60. 7.10.5 FUJIFILM Corporation Recent Developments
  61. 7.11 KoninklijikePhilips N.V.
  62. 7.11.1 KoninklijikePhilips N.V. Company Information
  63. 7.11.2 KoninklijikePhilips N.V. Business Overview
  64. 7.11.3 KoninklijikePhilips N.V. Lung Cancer Diagnostic And Screening Revenue and Gross Margin (2021-2026)
  65. 7.11.4 KoninklijikePhilips N.V. Lung Cancer Diagnostic And Screening Product Portfolio
  66. 7.11.5 KoninklijikePhilips N.V. Recent Developments
  67. 7.12 GE Healthcare Bio Sciences AB
  68. 7.12.1 GE Healthcare Bio Sciences AB Company Information
  69. 7.12.2 GE Healthcare Bio Sciences AB Business Overview
  70. 7.12.3 GE Healthcare Bio Sciences AB Lung Cancer Diagnostic And Screening Revenue and Gross Margin (2021-2026)
  71. 7.12.4 GE Healthcare Bio Sciences AB Lung Cancer Diagnostic And Screening Product Portfolio
  72. 7.12.5 GE Healthcare Bio Sciences AB Recent Developments
  73. 7.13 Quest Diagnostics lIncorporated
  74. 7.13.1 Quest Diagnostics lIncorporated Company Information
  75. 7.13.2 Quest Diagnostics lIncorporated Business Overview
  76. 7.13.3 Quest Diagnostics lIncorporated Lung Cancer Diagnostic And Screening Revenue and Gross Margin (2021-2026)
  77. 7.13.4 Quest Diagnostics lIncorporated Lung Cancer Diagnostic And Screening Product Portfolio
  78. 7.13.5 Quest Diagnostics lIncorporated Recent Developments
  79. 7.14 Agilent Technologies lnc
  80. 7.14.1 Agilent Technologies lnc Company Information
  81. 7.14.2 Agilent Technologies lnc Business Overview
  82. 7.14.3 Agilent Technologies lnc Lung Cancer Diagnostic And Screening Revenue and Gross Margin (2021-2026)
  83. 7.14.4 Agilent Technologies lnc Lung Cancer Diagnostic And Screening Product Portfolio
  84. 7.14.5 Agilent Technologies lnc Recent Developments
  85. 7.15 Qiagen Inc.
  86. 7.15.1 Qiagen Inc. Company Information
  87. 7.15.2 Qiagen Inc. Business Overview
  88. 7.15.3 Qiagen Inc. Lung Cancer Diagnostic And Screening Revenue and Gross Margin (2021-2026)
  89. 7.15.4 Qiagen Inc. Lung Cancer Diagnostic And Screening Product Portfolio
  90. 7.15.5 Qiagen Inc. Recent Developments
  91. 7.16 Myriad Genetic Laboratories Inc.
  92. 7.16.1 Myriad Genetic Laboratories Inc. Company Information
  93. 7.16.2 Myriad Genetic Laboratories Inc. Business Overview
  94. 7.16.3 Myriad Genetic Laboratories Inc. Lung Cancer Diagnostic And Screening Revenue and Gross Margin (2021-2026)
  95. 7.16.4 Myriad Genetic Laboratories Inc. Lung Cancer Diagnostic And Screening Product Portfolio
  96. 7.16.5 Myriad Genetic Laboratories Inc. Recent Developments
  97. 7.17 NeoGenomics Laboratories Inc
  98. 7.17.1 NeoGenomics Laboratories Inc Company Information
  99. 7.17.2 NeoGenomics Laboratories Inc Business Overview
  100. 7.17.3 NeoGenomics Laboratories Inc Lung Cancer Diagnostic And Screening Revenue and Gross Margin (2021-2026)
  101. 7.17.4 NeoGenomics Laboratories Inc Lung Cancer Diagnostic And Screening Product Portfolio
  102. 7.17.5 NeoGenomics Laboratories Inc Recent Developments
  103. 7.18 Canon MedicalSystems Corporation
  104. 7.18.1 Canon MedicalSystems Corporation Company Information
  105. 7.18.2 Canon MedicalSystems Corporation Business Overview
  106. 7.18.3 Canon MedicalSystems Corporation Lung Cancer Diagnostic And Screening Revenue and Gross Margin (2021-2026)
  107. 7.18.4 Canon MedicalSystems Corporation Lung Cancer Diagnostic And Screening Product Portfolio
  108. 7.18.5 Canon MedicalSystems Corporation Recent Developments
  109. 7.19 Eon Health Inc
  110. 7.19.1 Eon Health Inc Company Information
  111. 7.19.2 Eon Health Inc Business Overview
  112. 7.19.3 Eon Health Inc Lung Cancer Diagnostic And Screening Revenue and Gross Margin (2021-2026)
  113. 7.19.4 Eon Health Inc Lung Cancer Diagnostic And Screening Product Portfolio
  114. 7.19.5 Eon Health Inc Recent Developments
8 North America
  1. 8.1 North America Lung Cancer Diagnostic And Screening Revenue (2021-2032)
  2. 8.2 North America Lung Cancer Diagnostic And Screening Revenue by Type (2021-2032)
  3. 8.2.1 North America Lung Cancer Diagnostic And Screening Revenue by Type (2021-2026)
  4. 8.2.2 North America Lung Cancer Diagnostic And Screening Revenue by Type (2027-2032)
  5. 8.3 North America Lung Cancer Diagnostic And Screening Revenue Share by Type (2021-2032)
  6. 8.4 North America Lung Cancer Diagnostic And Screening Revenue by Application (2021-2032)
  7. 8.4.1 North America Lung Cancer Diagnostic And Screening Revenue by Application (2021-2026)
  8. 8.4.2 North America Lung Cancer Diagnostic And Screening Revenue by Application (2027-2032)
  9. 8.5 North America Lung Cancer Diagnostic And Screening Revenue Share by Application (2021-2032)
  10. 8.6 North America Lung Cancer Diagnostic And Screening Revenue by Country
  11. 8.6.1 North America Lung Cancer Diagnostic And Screening Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Lung Cancer Diagnostic And Screening Revenue by Country (2021-2026)
  13. 8.6.3 North America Lung Cancer Diagnostic And Screening Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Lung Cancer Diagnostic And Screening Revenue (2021-2032)
  2. 9.2 Europe Lung Cancer Diagnostic And Screening Revenue by Type (2021-2032)
  3. 9.2.1 Europe Lung Cancer Diagnostic And Screening Revenue by Type (2021-2026)
  4. 9.2.2 Europe Lung Cancer Diagnostic And Screening Revenue by Type (2027-2032)
  5. 9.3 Europe Lung Cancer Diagnostic And Screening Revenue Share by Type (2021-2032)
  6. 9.4 Europe Lung Cancer Diagnostic And Screening Revenue by Application (2021-2032)
  7. 9.4.1 Europe Lung Cancer Diagnostic And Screening Revenue by Application (2021-2026)
  8. 9.4.2 Europe Lung Cancer Diagnostic And Screening Revenue by Application (2027-2032)
  9. 9.5 Europe Lung Cancer Diagnostic And Screening Revenue Share by Application (2021-2032)
  10. 9.6 Europe Lung Cancer Diagnostic And Screening Revenue by Country
  11. 9.6.1 Europe Lung Cancer Diagnostic And Screening Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Lung Cancer Diagnostic And Screening Revenue by Country (2021-2026)
  13. 9.6.3 Europe Lung Cancer Diagnostic And Screening Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Lung Cancer Diagnostic And Screening Revenue (2021-2032)
  2. 10.2 China Lung Cancer Diagnostic And Screening Revenue by Type (2021-2032)
  3. 10.2.1 China Lung Cancer Diagnostic And Screening Revenue by Type (2021-2026)
  4. 10.2.2 China Lung Cancer Diagnostic And Screening Revenue by Type (2027-2032)
  5. 10.3 China Lung Cancer Diagnostic And Screening Revenue Share by Type (2021-2032)
  6. 10.4 China Lung Cancer Diagnostic And Screening Revenue by Application (2021-2032)
  7. 10.4.1 China Lung Cancer Diagnostic And Screening Revenue by Application (2021-2026)
  8. 10.4.2 China Lung Cancer Diagnostic And Screening Revenue by Application (2027-2032)
  9. 10.5 China Lung Cancer Diagnostic And Screening Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Lung Cancer Diagnostic And Screening Revenue (2021-2032)
  2. 11.2 Asia Lung Cancer Diagnostic And Screening Revenue by Type (2021-2032)
  3. 11.2.1 Asia Lung Cancer Diagnostic And Screening Revenue by Type (2021-2026)
  4. 11.2.2 Asia Lung Cancer Diagnostic And Screening Revenue by Type (2027-2032)
  5. 11.3 Asia Lung Cancer Diagnostic And Screening Revenue Share by Type (2021-2032)
  6. 11.4 Asia Lung Cancer Diagnostic And Screening Revenue by Application (2021-2032)
  7. 11.4.1 Asia Lung Cancer Diagnostic And Screening Revenue by Application (2021-2026)
  8. 11.4.2 Asia Lung Cancer Diagnostic And Screening Revenue by Application (2027-2032)
  9. 11.5 Asia Lung Cancer Diagnostic And Screening Revenue Share by Application (2021-2032)
  10. 11.6 Asia Lung Cancer Diagnostic And Screening Revenue by Country
  11. 11.6.1 Asia Lung Cancer Diagnostic And Screening Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Lung Cancer Diagnostic And Screening Revenue by Country (2021-2026)
  13. 11.6.3 Asia Lung Cancer Diagnostic And Screening Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Lung Cancer Diagnostic And Screening Revenue (2021-2032)
  2. 12.2 SAMEA Lung Cancer Diagnostic And Screening Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Lung Cancer Diagnostic And Screening Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Lung Cancer Diagnostic And Screening Revenue by Type (2027-2032)
  5. 12.3 SAMEA Lung Cancer Diagnostic And Screening Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Lung Cancer Diagnostic And Screening Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Lung Cancer Diagnostic And Screening Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Lung Cancer Diagnostic And Screening Revenue by Application (2027-2032)
  9. 12.5 SAMEA Lung Cancer Diagnostic And Screening Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Lung Cancer Diagnostic And Screening Revenue by Country
  11. 12.6.1 SAMEA Lung Cancer Diagnostic And Screening Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Lung Cancer Diagnostic And Screening Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Lung Cancer Diagnostic And Screening Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst